IRIS
JAFFRAIN, MARIE LISE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.199
AS - Asia 2.813
EU - Europa 2.806
SA - Sud America 282
AF - Africa 42
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 8
Totale 11.162
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.128
SG - Singapore 1.133
IE - Irlanda 662
CN - Cina 614
RU - Federazione Russa 538
IT - Italia 347
TR - Turchia 320
SE - Svezia 304
VN - Vietnam 295
HK - Hong Kong 271
DE - Germania 251
BR - Brasile 234
GB - Regno Unito 197
UA - Ucraina 176
FR - Francia 130
FI - Finlandia 102
CA - Canada 44
BD - Bangladesh 28
IN - India 26
JP - Giappone 26
BE - Belgio 22
ES - Italia 19
MX - Messico 19
NL - Olanda 15
CZ - Repubblica Ceca 14
IQ - Iraq 14
AR - Argentina 13
VE - Venezuela 12
AU - Australia 10
DZ - Algeria 9
ID - Indonesia 9
KR - Corea 9
SA - Arabia Saudita 9
PK - Pakistan 8
ZA - Sudafrica 8
EU - Europa 7
IL - Israele 7
KZ - Kazakistan 7
MA - Marocco 7
EC - Ecuador 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
AT - Austria 5
PL - Polonia 5
PY - Paraguay 5
UY - Uruguay 5
CO - Colombia 4
KE - Kenya 4
LT - Lituania 4
AL - Albania 3
JO - Giordania 3
LB - Libano 3
MY - Malesia 3
NP - Nepal 3
PT - Portogallo 3
UZ - Uzbekistan 3
BH - Bahrain 2
KH - Cambogia 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
SC - Seychelles 2
TT - Trinidad e Tobago 2
AO - Angola 1
BF - Burkina Faso 1
BZ - Belize 1
CL - Cile 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EG - Egitto 1
GE - Georgia 1
GN - Guinea 1
GP - Guadalupe 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
MN - Mongolia 1
NI - Nicaragua 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 11.162
Salva come PNG Salva come JPEG
Città #
Jacksonville 701
Chandler 682
Singapore 681
Dublin 662
San Jose 508
Dallas 384
Ashburn 268
Boardman 267
Hong Kong 267
Santa Clara 260
Council Bluffs 219
The Dalles 159
Izmir 148
Nanjing 124
San Mateo 124
New York 122
L’Aquila 114
Moscow 109
Wilmington 102
Lawrence 98
Princeton 98
Ho Chi Minh City 84
Ann Arbor 80
Lauterbourg 72
Beijing 60
Hanoi 60
Dong Ket 48
Milan 45
Des Moines 40
Nanchang 39
Hefei 38
Woodbridge 34
Dearborn 33
Los Angeles 32
Shenyang 30
L'aquila 29
Munich 29
Verona 28
Hebei 27
Mountain View 25
Seattle 25
Jiaxing 24
São Paulo 24
Tokyo 24
Kunming 23
San Francisco 23
Tianjin 22
Brussels 20
Frankfurt am Main 20
Rome 20
Brooklyn 18
Columbus 18
Helsinki 18
Toronto 18
Guangzhou 17
Orem 16
Shanghai 14
Changsha 13
Jinan 13
Brno 10
Mexico City 10
Montreal 10
Ningbo 10
Norwalk 9
Atlanta 8
Falkenstein 8
Falls Church 8
Haiphong 8
London 8
Philadelphia 8
Pune 8
Zhengzhou 8
Biên Hòa 7
Caracas 7
Da Nang 7
Rio de Janeiro 7
Stockholm 7
Baghdad 6
Changchun 6
Ninh Bình 6
Bremen 5
Charlotte 5
Montevideo 5
Mumbai 5
Nuremberg 5
Padova 5
Paris 5
Pescara 5
Taizhou 5
Amsterdam 4
Capistrello 4
Chengdu 4
Curitiba 4
Fremont 4
Houston 4
Jakarta 4
Johannesburg 4
Manchester 4
Melbourne 4
Miami 4
Totale 7.555
Salva come PNG Salva come JPEG
Nome #
AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. 187
18F-DOPA PET/CT Physiological Distribution and Pitfalls: Experience in 215 Patients 173
L'acromégalie familiale: A propos d'une observation, revue de la littérature 157
X-linked acrogigantism syndrome: Clinical profile and therapeutic responses 156
The R304X mutation of the Aryl hydrocarbon receptor Interacting Protein (AIP) gene in familial isolated pituitary adenomas: mutational Hot-Spot or founder effect? 150
Le forme familiari di adenoma ipofisario 144
p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumors 139
15 year-old boy with ocular palsy and headache. Invasive macroprolactinoma 133
Contenuto dei grassi nella dieta e rischio di insorgenza di carcinoma della mammella. 131
Clinical and genetic characterization of pituitary gigantism: An international collaborative study in 208 patients 127
How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020 126
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly 125
High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. 124
Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pitutuitary adenomas: pathological and clinical implications 124
Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells 124
Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors 122
Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: long-term clinical outcomes and volumetric MRI assessment of tumor response. 120
Two familial giant pituitary adenomas associated with overweight: clinical, morphological and genetic features 118
Hypophysitis 118
A Study of Alternative TrkA Splicing Identifies TrkAIII as a Novel Potentially Targetable Participant in PitNET Progression 118
Hypophysitis and Granulomatous Pituitary Lesions in Systemic Diseases 117
A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC 116
HMGA1-pseudogene expression is induced in human pituitary tumors 116
Clinical characterization of familial isolated pituitary adenomas 114
Aggressive prolactinoma in a child related to germline mutation in the Aryl hydrocarbon receptor Interacting Protein (AIP) gene. 114
Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas 114
New insights in the pathogenesis of pituitary tumours 114
Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families 113
From resistant to aggressive and malignant prolactinomas: a translational approach 113
Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly 112
Salivary gland tissues and derived primary and metastatic neoplasms: unusual pitfalls in the work-up of sellar lesions. A systematic review 112
Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients 111
Hyperplasia-adenoma sequence in pituitary tumorigenesis related to Aryl hydrocarbon receptor Interacting Protein gene mutation. 110
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. 110
Expression of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) in Non-Somatotroph Pituitary Tumours and the Effects of PPARα Agonists on MMQ Cells 110
Macroprolactinomas as a cause of delayed puberty: a report of two cases and effects of medical therapy 109
A critical re-appraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas 109
Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature 109
Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. 109
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician’s questions 108
Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art 107
Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study 107
Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients 107
Comparison of six-months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study 106
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy inpatients with prolactin-secreting pituitary adenomas 106
Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrine follow-up results 105
Effects of gonadal steroids on the growth of human pituitary adenomas in vitro 105
Relationship between blood pressure and glucose tolerance in acromegaly 105
Clinical and genetic features of familial pituitary adenomas 105
Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors 105
The genetics of pituitary adenomas 104
Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring 104
Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas 103
Expression of Epidermal Growth Factor in neoplastic pituitary cells: evidence for a role in corticotrophinoma cells 102
Il ruolo dell'endocrinologo nel trattamento delle lesioni della regione sellare 102
Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. 102
Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications 101
Cardiac effects of SR-Lanreotide, a slow-release somatostatin analog, in acromegalic patients 101
Familial pituitary adenomas. 101
Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics 100
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database 100
The prevalence of silent acromegaly in prolactinomas is very low 100
Influence of radiotherapy on long-term follow-up of clinically non-secreting pituitary adenomas 98
A multivariable prediction model for pegvisomant dosing: Monotherapy and in combination with long-acting somatostatin analogues 98
Infusione sequenziale di GHRH 1-29NH2, LHRH e TRH per la valutazione della riserva ipofisaria: confronto con il Politest. 97
De la génétique des adénomes hypophysaires 97
Prognostic Factors: Molecular Pathway – Tumour Suppressor Gene (MEN1) 97
A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal 96
Familial pituitary adenomas: from clinical practice to basic research 95
Surgical treatment and clinical outcome of GH-secreting adenomas in elderly patients 94
Effect of 17β-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas. Correlation with specific cellular receptors 93
Two-year follow-up of acromegalic patients treated with slow release Lanreotide (30 mg) 91
Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly 91
Sellar and parasellar lesions in the transition age: a retrospective Italian multi-centre study 89
HPLC determination of urinary catecholamines as a screening test for pheochromocytoma in a patient with medullary carcinoma of the thyroid. 89
Human pituitary tumours express the bHLH transcription factors NeuroD1 and ASH1 89
Evaluation of the adequacy of Levothyroxine replacement therapy in patients with central hypothyroidism 89
Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution 89
Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update 89
Pituitary adenomas in young patients: when should we consider a genetic predisposition? 88
Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects 88
The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas 87
Prevalence of silent acromegaly in prolactinomas (PASP): an Italian experience 86
Radiotherapy for nonfunctioning pituitary adenomas: from conventional to modern stereotactic radiation techniques. 85
Cellular receptors for sex steroids in human pituitary adenomas 84
Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene 84
Clinical and Molecular Characteristics of Gonadotroph Pituitary Tumors According to the WHO Classification 84
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. 83
Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. 82
Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion 81
Epidermal growth factor (EGF)- binding sites in human pituitary adenomas 81
Fenofibrate has differential effects on cell proliferation and GH secretion in GH3 cells 81
Long-term follow-up results of postoperative radiation therapy for Cushing's disease 80
Surgical treatment of pituitary tumours in the elderly: clinical outcome and long-term follow-up 80
Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure ? An audit of surgical results on a large series and a review of the literature 80
Visual improvement during octreotide therapy in a case of episellar meningioma 80
The Role of Aryl Hydrocarbon Receptor (AHR) and AHR-Interacting Protein (AIP) in the Pathogenesis of Pituitary Adenomas 79
Giant prolactinomas presenting as skull base tumors 78
Mir-23b and miR-130b expression is downregulated in pituitary adenomas 77
Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients 76
Totale 10.539
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.501
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.501
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022676 34 56 120 35 36 7 5 44 37 7 33 262
2022/20231.879 136 112 74 173 163 215 2 116 792 5 64 27
2023/2024528 159 29 19 69 33 136 9 13 2 15 12 32
2024/20251.826 47 27 180 35 292 148 223 176 383 61 155 99
2025/20263.573 137 342 267 294 302 268 713 185 313 379 324 49
2026/202775 75 0 0 0 0 0 0 0 0 0 0 0
Totale 11.282